The role of lung cancer risk and comorbidity in lung cancer screening use

• Published in: Preventive medicine reports 2022-12, Vol.30, p.102006-102006, Article 102006
• Main Authors: Richman, Ilana B., Long, Jessica B., Poghosyan, Hermine, Sather, Polly, Gross, Cary P.
• Format: Article
• Language: English
• Subjects: decision-making; lung cancer risk; Lung cancer screening; Short Communication
• ISSN: 2211-3355; 2211-3355
• DOI: 10.1016/j.pmedr.2022.102006

Although lung cancer screening (LCS) with low dose computed tomography has been shown to reduce lung cancer mortality, benefits and harms of screening vary among eligible adults. The goal of this study was to evaluate whether LCS is more commonly used among populations most likely to benefit, namely adults with high lung cancer risk and low comorbidity. In this cohort study of patients eligible for LCS, we used data from the electronic health record to evaluate the relationship between lung cancer risk, comorbidity, and receipt of LCS. We also evaluated use of diagnostic chest CT. Analyses used a nonparametric test for trend across quartiles of lung cancer risk and comorbidity. The study sample included 551 LCS-eligible adults who were followed for a mean 2.9 years (SD 1.6 years). A cumulative 190 (34 %) received at least 1 LCS, and 141 (26 %) had a diagnostic chest CT. Receipt of LCS increased across quartiles of lung cancer risk (5 per 100 person years in the lowest quartile vs 13 per 100 person-years in the highest, p